+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Interleukin Inhibitors Market by Product and Geography - Global Forecast and Analysis 2019-2023 - Product Image

Interleukin Inhibitors Market by Product and Geography - Global Forecast and Analysis 2019-2023

  • ID: 4828979
  • Report
  • Region: Global
  • 137 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
Global Interleukin Inhibitors Market: About this market

The Interleukin inhibitors market analysis considers sales from Interleukin-23 inhibitors, Interleukin-17 inhibitors, Interleukin-6 inhibitors, and other Interleukin inhibitors. The analysis also considers the sales of Interleukin inhibitors in Asia, Europe, North America, and ROW. In 2018, the Interleukin-23 inhibitors segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high prevalence of psoriasis and improved R&D on Interleukin-23 inhibitors will help in the growth of Interleukin-23 inhibitors segment and maintain its market position. Also, the global Interleukin inhibitors market report looks at factors such as high target affinity and specificity of Interleukin inhibitors, recent approvals and robust pipeline, and presence of reimbursement and patient assistance program. However, availability of substitutes, product withdrawals and failure of clinical trials, and adverse side effects and high cost of Interleukin inhibitors may hamper the growth of the Interleukin inhibitors industry over the forecast period.

Global Interleukin Inhibitors Market: Overview

High target affinity and specificity of Interleukin inhibitors

Interleukin inhibitors are target specific and work directly in Interleukin receptors. These drugs are highly effective in the treatment of autoimmune diseases such as psoriasis, rheumatoid arthritis, and Crohn’s disease. Higher patient adherence to these drugs because of their higher affinity and specificity. The advances in the R&D Interleukin drugs and clinical trials for late-stage molecules is expected to lead the expansion of the global Interleukin inhibitors market at a CAGR of almost 13% during the forecast period.

Increasing awareness about autoimmune diseases

The major focus of the awareness programs is to educate people about the symptoms of various arthritis indications, cause of the diseases, risk factors that cause inflammation, availability of various treatments and preventive measures that can be taken to control the disease. These awareness campaigns are expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global Interleukin inhibitors market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Interleukin inhibitors manufacturers, that include Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG, Regeneron Pharmaceuticals Inc.

Also, the Interleukin inhibitors analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Interleukin-23 inhibitors - Market size and forecast 2018-2023
  • Interleukin-17 inhibitors - Market size and forecast 2018-2023
  • Interleukin-6 inhibitors - Market size and forecast 2018-2023
  • Other Interleukin inhibitors - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Increasing awareness about autoimmune diseases
  • Strategic alliances
  • Introduction of biosimilars
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Interleukin-23 inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Interleukin-23 inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 22: Interleukin-17 inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Interleukin-17 inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 24: Interleukin-6 inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Interleukin-6 inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 26: Other Interleukin inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Other Interleukin inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Recently approved Interleukin inhibitor molecules
Exhibit 47: Some of the late-stage pipeline molecules
Exhibit 48: Some of the available substitutes for Interleukin inhibitors
Exhibit 49: Some of the serious side effects of Interleukin inhibitors are listed below:
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Vendor landscape
Exhibit 52: Landscape disruption
Exhibit 53: Vendors covered
Exhibit 54: Vendor classification
Exhibit 55: Market positioning of vendors
Exhibit 56: Eli Lilly and Co. - Vendor overview
Exhibit 57: Eli Lilly and Co. - Product segments
Exhibit 58: Eli Lilly and Co. - Organizational developments
Exhibit 59: Eli Lilly and Co. - Geographic focus
Exhibit 60: Eli Lilly and Co. - Segment focus
Exhibit 61: Eli Lilly and Co. - Key offerings
Exhibit 62: Eli Lilly and Co. - Key customers
Exhibit 63: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 64: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 65: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 66: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 67: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 68: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 69: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 70: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 71: Johnson & Johnson Services, Inc. - Business segments
Exhibit 72: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 73: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 74: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 75: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 76: Johnson & Johnson Services, Inc. - Key customers
Exhibit 77: Novartis AG - Vendor overview
Exhibit 78: Novartis AG - Business segments
Exhibit 79: Novartis AG - Organizational developments
Exhibit 80: Novartis AG - Geographic focus
Exhibit 81: Novartis AG - Segment focus
Exhibit 82: Novartis AG - Key offerings
Exhibit 83: Novartis AG - Key customers
Exhibit 84: Regeneron Pharmaceuticals Inc. - Vendor overview
Exhibit 85: Regeneron Pharmaceuticals Inc. - Business segments
Exhibit 86: Regeneron Pharmaceuticals Inc. - Organizational developments
Exhibit 87: Regeneron Pharmaceuticals Inc. - Key offerings
Exhibit 88: Regeneron Pharmaceuticals Inc. - Key customers
Exhibit 89: Validation techniques employed for market sizing
Exhibit 90: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
The following companies are recognised as the key players in the global Interleukin inhibitors market: Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG, Regeneron Pharmaceuticals Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is increasing awareness about autoimmune diseases.”

According to the report, one of the major drivers for this market is the high target affinity and specificity of Interleukin inhibitors.

Further, the report states that one of the major factors hindering the growth of this market is the adverse side effects and high cost of Interleukin inhibitors
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
Note: Product cover images may vary from those shown
Adroll
adroll